TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06453122

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Oral care
Description: The intervention group procedure will be carried out in the same way and frequency of the control group, however, replacing the chlorhexidine solution 0.12% for mineral water. Oral hygiene will be carried out by the nursing team, which will be blind to the indices to be evaluated. The team will be previously trained to carry out hygiene procedures by the team of ICU dental surgeons.
Study: NCT05297474

Intervention type: OTHER
Intervention: MRI
Description: No intervention was performed in this study.

Intervention type: OTHER
Intervention: MRI
Description: No intervention was performed in this study.
Study: NCT06197555

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Monofluorophosphate
Description: Test toothpaste, participants will brush selected sensitive teeth each for 30 seconds followed by the whole mouth thoroughly for at least one minute. The method of application of these agents will be the fingertip method. Patients continued to use the paste twice daily, morning and evening, for 16 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stannous Fluoride
Description: Test toothpaste, participants will brush selected sensitive teeth each for 30 seconds followed by the whole mouth thoroughly for at least one minute. The method of application of these agents will be the fingertip method. Patients continued to use the paste twice daily, morning and evening, for 16 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nano-Hydroxyapatite
Description: Test toothpaste, participants will brush selected sensitive teeth each for 30 seconds followed by the whole mouth thoroughly for at least one minute. The method of application of these agents will be the fingertip method. Patients continued to use the paste twice daily, morning and evening, for 16 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 8% Arginine & Calcium Carbonate
Description: Test toothpaste, participants will brush selected sensitive teeth each for 30 seconds followed by the whole mouth thoroughly for at least one minute. The method of application of these agents will be the fingertip method. Patients continued to use the paste twice daily, morning and evening, for 16 weeks.
Study: NCT04569500

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PETAL program
Description: patients and their close relations will benefit from the therapeutic education program PETAL in order to accompany them throughout their experience of laryngectomy and to reduce its impact on social and professional aspects of life.
Study: NCT05882474

Intervention type: DEVICE
Intervention: PaCO2
Description: Level of partial pressure of carbon dioxide
Study: NCT06408857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAM01 150 mg SC
Description: MAM01 150 mg will be administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAM01 150 mg SC
Description: MAM01 150 mg will be administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAM01 100 mg SC
Description: MAM01 100 mg will be administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAM01 150 mg IM
Description: MAM01 150 mg will be administered IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAM01 150 mg IV
Description: MAM01 150 mg will be administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo SC
Description: Placebo will be administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo SC
Description: Placebo will be administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo SC
Description: Placebo will be administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo SC
Description: Placebo will be administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo SC
Description: Placebo will be administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo IV
Description: Placebo will be administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo IM
Description: Placebo will be administered IM
Study: NCT05511467

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visuomotor learning task
Description: Participants undergo functional magnetic resonance imaging during the performance of the visuomotor learning task. The visuomotor learning task involves holding a device in the hand that measures the strength of the grip when squeezing the 'gripper'.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visuomotor learning task
Description: Participants undergo functional magnetic resonance imaging during the performance of the visuomotor learning task. The visuomotor learning task involves holding a device in the hand that measures the strength of the grip when squeezing the 'gripper'.
Study: NCT06172907

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Young Adults Coping with Cancer Together Intervention
Description: This intervention is based on cognitive-behavioral therapy and couples' therapy. It aims to improve cancer and caregiving-related self-efficacy and coping, as well as promote relationship maintenance in context of cancer. The intervention will be delivered by a trained mental health practitioner and include didactics, experiential exercises, and home practice.
Study: NCT06475937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DM001
Description: Subjects may continue to receive DM001 (with an increased dose that has been assessed as safe in the dose-escalation period) once every 3 weeks (Q3W) for a total of 6 cycles at the discretion of the investigators, until unacceptable toxicity, progressive disease (PD), or withdrawal of consent.
Study: NCT06068881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazverik (Tazemetostat)
Description: Oral Tablet
Study: NCT06547008

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Army-SPRING
Description: Army-SPRING includes a package of implementation options to support implementation of ASIST.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Risk Reduction Group (Control)
Description: Risk Reduction Group is a mandated training from National Guard Service members
Study: NCT04210284

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ensure
Description: Ensure Max Protein Shake is an over the counter available drinkable nutritional supplement. Per serving, it contains:~* 160 Calories, 20 from fat~* 2g Total fat~* 0.5g Saturated fat~* 20mg Cholesterol~* 135mg Sodium~* 170mg Potassium~* 19g Total carbohydrate~* \<1g Fiber~* 4g Sugar~* 16g Protein~Participants will receive Ensure High Protein for 2 weeks pre- and 4 weeks post-operatively. These patients will be instructed to consume 1 serving (16fl oz) of Ensure High Protein daily. They will be provided with this product at a pre-operative clinical visit or have it mailed to their home. Hematologic nutritional values will be measured as specified previously.~Descriptive statistics will be used to report baseline characteristics and primary study objectives. Hematologic outcomes will be compared between the control (NO ENSURE) and oral supplementation (ENSURE) arms for the aforementioned baseline and perioperative variables
Study: NCT01539876

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fine needle aspiration assessing tumour TNFa levels
Description: Fine Needle aspiration will be done X5: 1 hr pre-treatment, 1hr post treatment,24 hrs post treatment, 48 hrs post treatment, and following last chemotherapy cycle
Study: NCT05716477

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: OTHER
Intervention: Survey Administration
Description: Complete survey
Study: NCT04660344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participants will receive 1680 mg intravenously every 4 weeks (Q4W) on Day 1 of each 28-day cycle.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo intravenously Q4W on Day 1 of each 28-day cycle
Study: NCT04761276

Intervention type: DEVICE
Intervention: Surgical implantation of intra ocular lens
Description: Cataract surgery may be indicated when the cataract reduces visual function to a level that interferes with everyday activities of the patient leading the patient to desire a surgical intervention to improve its vision.
Study: NCT05075408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemolizumab
Description: Participants will receive 2 subcutaneous injections for a total dose of 30 milligrams (mg) of nemolizumab every 4 weeks (Q4W), with a loading dose of 60 mg at baseline for a period of 12 weeks with an 8 week follow-up.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemolizumab
Description: Participants will receive 2 subcutaneous injections of 30 mg of nemolizumab Q4W starting at baseline for a period of 12 weeks with an 8 week follow-up.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive 2 subcutaneous injections of 30 mg of placebo-matched to nemolizumab Q4W for a period of 12 weeks with an 8 week follow-up.
Study: NCT05514262

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The stress ball
Description: Covid-19 vaccination procedure with individuals in the stress ball group: With this group, a yellow stress ball will be used which is 6cm in diameter, of medium hardness and made of high quality silicone, and which returns to its original shape after being squeezed. The researcher will explain to the individuals in the group how they should use the stress ball five minutes before beginning the vaccination and during the procedure. The individuals will be taught to take the stress ball in their right hand, the side on which the vaccination will not be given, and, counting from one to three, to squeeze and release the ball, continuing until the procedure is finished. It will be explained that during the procedure, they should give their attention to the stress ball and focus on squeezing it.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Buzzy® device
Description: Covid-19 vaccination procedure with individuals in the Buzzy® group: Individuals in this group will use the Buzzy® device. Before the vaccination procedure, the researcher will place the Buzzy® device, which will be at room temperature, on the vaccination site, and it will vibrate in a non-discomforting way for one minute. After this, the Buzzy® device will be removed from the site, and the nurse will perform the vaccination. Because Buzzy® is a device which can be re-used, it will be disinfected after each vaccination procedure, and re-used with other individuals. The Buzzy® device also has ice wings which will not be used in this study, and only the body of the device will be used to provide vibration.
Study: NCT04861259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crovalimab
Description: Crovalimab will be administered at a dose of 1000 milligrams (mg) intravenous (IV) (for participants with body weight at least 40 (\>=) and up to 100 kilograms (kg) or 1500 mg IV (for participants with body weight \>=100kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, it will be administered at a dose of 340 mg subcutaneously (SC). On Week 5 and every 4 weeks (Q4W) thereafter, it will be administered at a dose of 680 mg SC (for participants with body weight \>= 40kg to \<100kg) or 1020 mg SC (for participants with body weight \>=100kg).
Study: NCT05894798

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture at point LI 4 in the thumb grip on the upper side of the hand, bilaterally, with a sterile disposable needle of dimension 0.20 x 13 mm. The stitch is approximately three mm deep. The needle is allowed to remain in place for about 30 seconds
Study: NCT05687903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-861
Description: TAK-861 oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-861
Description: TAK-861 oral tablets
Study: NCT05517109

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hemodynamic goal including lower goal of systolic blood pressure
Description: Different hemodynamic goals in different study arms
Study: NCT05600309

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: favezelimab/pembrolizumab
Description: Coformulated favezelimab/pembrolizumab (800 mg/200 mg), IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: regorafenib
Description: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAS-102
Description: Oral
Study: NCT04870424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Colchicine in a loading dosage of 1mg single dose per os the day before TAVI and 1mg single dose at the day of procedure. Thereafter, colchicine 0.5mg once daily per os up to post-procedural day 12.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily per os the day before TAVI and once at the day of procedure. Thereafter, once daily per os up to post-procedural day 12.
Study: NCT05687903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-861
Description: TAK-861 oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-861
Description: TAK-861 oral tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral tablets matching TAK-861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral tablets matching TAK-861
Study: NCT05982769

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endurance Training 3 times per week
Description: endurance training will be performed from home 3 times per week under the supervision of the research team.
Study: NCT03919695

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kisoboka: Behavioral and Structural Intervention
Description: The intervention has two components; a structural component and a behavioral component. The intervention draws from behavioral economics and motivational interviewing.~Structural component: This component is about receiving work payments via mobile money instead of cash.~Behavioral component: This component includes feedback on alcohol screening, counseling, client-centered goal setting, self-monitoring, financial literacy training, and text message reminders of life/savings and healthy living goals.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Screening and Referral
Description: Alcohol screening and referral and emphasizing the importance of HIV care engagement and ART adherence
Study: NCT05507476

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desmopressin Acetate Nasal, 10 μg/0.1 ml per spray
Description: The patient will receive two puffs of desmopressin acetate 10 µg/puff in the side of the nasal cavity ipsilateral to the obstructed lacrimal duct (20 μg totally) 60 minutes before surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine topical 1:100,000 Nasal Packs
Description: The patient will receive topical 1:100,000 epinephrine in the side of the nasal cavity ipsilateral to the obstructed lacrimal gland via 3 soaked packs placed in the middle meatus for 5 minutes immediately before the start of surgery.
Study: NCT06554847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 611
Description: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 611
Description: subcutaneous injection
Study: NCT05982769

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: resistance training will be performed from home 2 times per week under the supervision of the research team.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: continue usual activity
Study: NCT05494424

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal Management Training (GMT)
Description: Goal Management Training is a cognitive rehabilitation intervention that relies on metacognitive strategies to reengage top-down attention processes, in addition to teaching problem-solving techniques, attempting to address executive dysfunctions.
Study: NCT05339412

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training Tool for Preventing HIV/AIDS among Teens (PHAT) Life
Description: The technology-based training tool will train facilitators to deliver the behavioral health intervention PHAT Life, which is an innovative HIV/STI, substance use, and mental health intervention for juvenile offenders. The training tool reviews each of PHAT Life's 8 sessions. The curriculum targets broad psychosocial factors implicated in HIV/STI-risk behavior, including promoting positive attitudes toward HIV/STI prevention, self-efficacy to reduce risk, and less substance misuse and sexual risk taking. Content emphasizes the importance of emotion regulation skills to manage strong feelings, uses goal setting and training in positive thought processes to plan ahead, encourages recognition of personal responsibility in future outcomes, and helps youth identify strategies and behaviors to accomplish short- and long-term goals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training Tool for Preventing HIV/AIDS among Teens (PHAT) Life
Description: The technology-based training tool will train facilitators to deliver the behavioral health intervention PHAT Life, which is an innovative HIV/STI, substance use, and mental health intervention for juvenile offenders. The training tool reviews each of PHAT Life's 8 sessions. The curriculum targets broad psychosocial factors implicated in HIV/STI-risk behavior, including promoting positive attitudes toward HIV/STI prevention, self-efficacy to reduce risk, and less substance misuse and sexual risk taking. Content emphasizes the importance of emotion regulation skills to manage strong feelings, uses goal setting and training in positive thought processes to plan ahead, encourages recognition of personal responsibility in future outcomes, and helps youth identify strategies and behaviors to accomplish short- and long-term goals.
Study: NCT06554847

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical corticosteroid
Description: Topical
Study: NCT06268041

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate-Intensity Aerobic Training
Description: Overground and treadmill walking with speed continuously adjusted to maintain a target heart rate of 40 +/- 5% heart rate reserve, progressing up to 55 +/- 5% heart rate reserve.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training
Description: Overground and treadmill walking with 30 second bursts at maximum speed alternated with 30-60 second passive recovery periods. Intended to achieve a target average heart rate above 60% heart rate reserve.
Study: NCT04999202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2416964
Description: Oral, twice or three times daily
Study: NCT06554847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical corticosteroid
Description: Topical

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical corticosteroid
Description: Topical
Study: NCT05230368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine cycle 1
Description: Decitabine administration (5mg/m²) at days 1, 2, 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine cycle 1
Description: Decitabine administration (5mg/m²) at days 1, 2, 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine cycle 1
Description: Decitabine administration (5mg/m²) at days 1, 2, 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin cycle 1
Description: Romidepsin administration (5mg/m²) at days 4, 11, 18

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin cycle 1
Description: Romidepsin administration (5mg/m²) at days 4, 11, 18

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin cycle 1
Description: Romidepsin administration (5mg/m²) at days 4, 11, 18

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine cycle 2
Description: Decitabine administration (5mg/m²) at days 35, 36, 37

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine cycle 2
Description: Decitabine administration (5mg/m²) at days 35, 36, 37

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin cycle 2
Description: Romidepsin administration (5mg/m²) at days 38, 45, 52

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin cycle 2
Description: Romidepsin administration (5mg/m²) at days 38, 45, 52

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine cycle 3
Description: Decitabine administration (5mg/m²) at days 70, 71, 72

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin cycle 3
Description: Romidepsin administration (5mg/m²) at days 73, 80, 87

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine cycle 4
Description: Decitabine administration (5mg/m²) at days 105, 106, 107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin cycle 4
Description: Romidepsin administration (5mg/m²) at days 108, 115, 122
Study: NCT06033430

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: True dry needling
Description: Prior to the procedure, participants will be given a detailed explanation of the dry needling technique. Afterward, the specific area will be thoroughly cleaned using an alcohol pad. In the true dry needling group, along with routine physiotherapy, a sterile filiform acupuncture needle, measuring 2 cm in length and designed for single-use, will be inserted at a 15-degree angle relative to the skin's surface, directly into the scar tissue. Once inserted, the needle will be gently rotated to aid in separating tissue adhesions along the path of the scar. Routine physiotherapy includes the application of kinesiology taping, in addition to a 20-minute session of infrared therapy positioned 30 cm away from the scar tissue. A total of six treatment sessions will be administered to the patients, with three sessions per week scheduled over a two-week period.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham dry needling
Description: The sham group participants will be positioned in a similar manner to those in the experimental group, with a minor exception. Instead of inserting the 2-cm single-use sterile filiform acupuncture needle into the scar tissue, it will be superficially inserted at a point further away from the scar tissue and removed after 20 minutes. Moreover, routine physiotherapy administered to the participants in the sham group will be identical to that of the experimental group, ensuring consistency between the two groups.